Citations

Citations to this article as recorded by  

• Saudi consensus guidance for the diagnosis and management of inflammatory bowel disease in children and adolescents
  Omar I. Saadah, Turki AlAmeel, Ahmed Al Sarkhy, Mohammed Hasosah, Abdulrahman Al-Hussaini, Majid A. Almadi, Badr Al-Bawardy, Talal A. Altuwaijri, Mohammed AlEdreesi, Shakir A. Bakkari, Othman R. Alharbi, Nahla A. Azzam, Abdulelah Almutairdi, Khalidah A. A
  Saudi Journal of Gastroenterology.2024;[Epub]     CrossRef
• The treatment of inflammatory bowel disease with monoclonal antibodies in Asia
  Yu Chen, Guolin Zhang, Yuewen Yang, Shuangshuang Zhang, Haozheng Jiang, Kang Tian, Arenbaoligao, Dapeng Chen
  Biomedicine & Pharmacotherapy.2023; 157: 114081.     CrossRef
• A Retrospective Cohort Study of Clinical Features and Treatment Patterns With Ustekinumab in Patients With Crohn Disease Utilizing a Health Care Database in Japan
  Yanfang Liu, Choo Hua Goh, Hong Qiu, Kuan-Chih Huang, Hsingwen Chung, Carine Saadoun
  Annals of Pharmacotherapy.2023; 57(9): 1053.     CrossRef
• Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study
  Kyunghwan Oh, Hee Seung Hong, Nam Seok Ham, Jungbok Lee, Sang Hyoung Park, Suk-Kyun Yang, Hyuk Yoon, You Sun Kim, Chang Hwan Choi, Byong Duk Ye
  Intestinal Research.2023; 21(1): 137.     CrossRef
• A critical review of ustekinumab for the treatment of active ulcerative colitis in adults
  Sophie Vieujean, Edouard Louis, Silvio Danese, Laurent Peyrin-Biroulet
  Expert Review of Gastroenterology & Hepatology.2023; 17(5): 413.     CrossRef
• Feasibility of a Clinical Decision Support Tool for Ustekinumab to Predict Clinical Remission and Relapse in Patients With Crohn’s Disease: A Multicenter Observational Study
  Jihye Park, Jaeyoung Chun, Hyuk Yoon, Jae Hee Cheon
  Inflammatory Bowel Diseases.2022;[Epub]     CrossRef
• Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs
  Soo-Young Na, You Sun Kim
  The Korean Journal of Internal Medicine.2022; 37(5): 906.     CrossRef
• Association of Anti–Tumor Necrosis Factor Therapy With Mortality Among Veterans With Inflammatory Bowel Disease
  Shirley Cohen-Mekelburg, Beth I. Wallace, Tony Van, Wyndy L. Wiitala, Shail M. Govani, Jennifer Burns, Rachel Lipson, Huifeng Yun, Jason Hou, James D. Lewis, Jason A. Dominitz, Akbar K. Waljee
  JAMA Network Open.2021; 4(3): e210313.     CrossRef
• Evidence-based clinical practice guidelines for inflammatory bowel disease 2020
  Hiroshi Nakase, Motoi Uchino, Shinichiro Shinzaki, Minoru Matsuura, Katsuyoshi Matsuoka, Taku Kobayashi, Masayuki Saruta, Fumihito Hirai, Keisuke Hata, Sakiko Hiraoka, Motohiro Esaki, Ken Sugimoto, Toshimitsu Fuji, Kenji Watanabe, Shiro Nakamura, Nagamu I
  Journal of Gastroenterology.2021; 56(6): 489.     CrossRef
• Safety and effectiveness of ustekinumab in Crohn's disease: Interim results of post‐marketing surveillance in Japan
  Seiji Yokoyama, Teita Asano, Katsumasa Nagano, Hiroaki Tsuchiya, Masayuki Takagishi, Shigeharu Tsujioka, Naomi Miura, Takayuki Matsumoto
  Journal of Gastroenterology and Hepatology.2021; 36(11): 3069.     CrossRef
• Translating Treg Therapy for Inflammatory Bowel Disease in Humanized Mice
  Sushmita Negi, Sheetal Saini, Nikunj Tandel, Kiran Sahu, Ravi P.N. Mishra, Rajeev K. Tyagi
  Cells.2021; 10(8): 1847.     CrossRef
• Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI)
  Tadakazu Hisamatsu, Hyo Jong Kim, Satoshi Motoya, Yasuo Suzuki, Yoshifumi Ohnishi, Noriyuki Fujii, Nobuko Matsushima, Richuan Zheng, Colleen W. Marano
  Intestinal Research.2021; 19(4): 386.     CrossRef
• Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis
  Taku Kobayashi, Hiroaki Ito, Toshifumi Ashida, Tadashi Yokoyama, Masakazu Nagahori, Tomoki Inaba, Mitsuhiro Shikamura, Takayoshi Yamaguchi, Tetsuharu Hori, Philippe Pinton, Mamoru Watanabe, Toshifumi Hibi
  Intestinal Research.2021; 19(4): 448.     CrossRef
• Interleukin 23 and autoimmune diseases: current and possible future therapies
  Ahmad Ismail Khaled Abdo, Gee Jun Tye
  Inflammation Research.2020; 69(5): 463.     CrossRef
• Long-Term Clinical Effectiveness of Ustekinumab in Patients With Crohn’s Disease: A Retrospective Cohort Study
  Takahiro Ito, Atsuo Maemoto, Takehiko Katsurada, Hiroki Tanaka, Satoshi Motoya, Nobuhiro Ueno, Mikihiro Fujiya, Toshifumi Ashida, Daisuke Hirayama, Hiroshi Nakase
  Crohn's & Colitis 360.2020;[Epub]     CrossRef
• Novel drug delivery systems of Chinese medicine for the treatment of inflammatory bowel disease
  Caifang Gao, Lijuan Liu, Yangyang Zhou, Zhaoxiang Bian, Shengpeng Wang, Yitao Wang
  Chinese Medicine.2019;[Epub]     CrossRef
• Ustekinumab is effective in biological refractory Crohn’s disease patients–regardless of approval study selection criteria
  Sadik Saman, Martin Goetz, Judith Wendler, Nisar P. Malek, Jan Wehkamp, Thomas Klag
  Intestinal Research.2019; 17(3): 340.     CrossRef
• Perspectives on Current and Novel Treatments for Inflammatory Bowel Disease
  Soo-Young Na, Won Moon
  Gut and Liver.2019; 13(6): 604.     CrossRef
• Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease
  Sarah C Davies, Tran M Nguyen, Claire E Parker, John K MacDonald, Vipul Jairath, Reena Khanna
  Cochrane Database of Systematic Reviews.2019;[Epub]     CrossRef
• Novel treatments for inflammatory bowel disease
  Hyo Sun Lee, Soo-Kyung Park, Dong Il Park
  The Korean Journal of Internal Medicine.2018; 33(1): 20.     CrossRef
• Emerging Therapies: What Are Promising in the Near Future?
  Geom Seog Seo, Sung Hee Lee
  The Korean Journal of Gastroenterology.2018; 71(2): 81.     CrossRef